AAM
PCVX icon

Advisors Asset Management’s Vaxcyte PCVX Stock Holding History

Advisors Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$112K Buy
1,921
+24
+1% +$1.3K ﹤0.01% 1241
2026
Q1 		$110K Sell
1,897
-25
-1% -$1.36K ﹤0.01% 1232
2025
Q4 		$88.7K Sell
1,922
-1
-0.1% -$45 ﹤0.01% 1241
2025
Q3 		$69.3K Sell
1,923
-7
-0.4% -$232 ﹤0.01% 1263
2025
Q2 		$62.7K Buy
1,930
+1
+0.1% +$33 ﹤0.01% 1266
2025
Q1 		$72.8K Buy
1,929
+867
+82% +$69.3K ﹤0.01% 1248
2024
Q4 		$86.9K Buy
+1,062
New +$105K ﹤0.01% 1244

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Advisors Asset Management's PCVX Position: Q2 2026 in Review

Advisors Asset Management increased its Vaxcyte (PCVX) stake by 1.3% in Q2 2026, buying an estimated $1.3K and bringing the position to 1,921 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #1241.

Advisors Asset Management first reported a position in PCVX in Q4 2024 and has held it in 7 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Advisors Asset Management held 1,921 shares of Vaxcyte worth $112K as of Q2 2026.
  • Advisors Asset Management bought 24 Vaxcyte shares in Q2 2026, an estimated $1.3K.
  • Vaxcyte made up ﹤0.01% of Advisors Asset Management's portfolio in Q2 2026, its #1241 holding.
  • Advisors Asset Management first reported a position in Vaxcyte in Q4 2024 and has held it in 7 quarters since.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.